EP. 3: BRCA Testing in Early-Stage and Metastatic Breast Cancer
February 3rd 2025Panelists discuss their approach to BRCA testing in early-stage versus metastatic breast cancer patients, highlighting the 2024 American Society of Clinical Oncology (ASCO) guidelines for germline testing and exploring which patients are not tested for BRCA, as well as how they differentiate between germline and somatic testing approaches.
EP. 4: OlympiA: Data Updates From SABCS 2024
February 3rd 2025Panelists review the recent OlympiA data presented at the 2024 San Antonio Breast Cancer Symposium (SABCS) and discuss how the findings influence their approach to sequencing adjuvant olaparib with other systemic therapies for breast cancer patients.
EP. 5: Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors
February 10th 2025Panelists discuss how recent data inform their approach to PARP inhibitor use in the metastatic setting, exploring the role of PARP inhibition for somatic BRCA mutations and strategies for managing PALB2 and other homologous recombination deficiency mutations.
EP. 6: KN-522: Clinical Implications and Insights Into Clinical Practice
February 10th 2025Panelists highlight the KN-522 study and discuss how updated KEYNOTE-522 data influence their selection of patients for pembrolizumab-containing regimens, focusing on factors that guide the decision to recommend immunotherapy and how to approach patients with borderline indications.
EP. 7: Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
February 17th 2025Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.
EP. 8: SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC
February 17th 2025Panelists discuss the most exciting data and studies presented at the San Antonio Breast Cancer Symposium (SABCS) that show promise for improving outcomes in both HR-positive (HR+) and HER2-negative (HER2–) metastatic breast cancer and early-stage triple-negative breast cancer (TNBC), highlighting how precision medicine has enhanced outcomes and the overall patient experience.